1y return+38.0%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2023: $205 against $157 in the S&P 500.2
Rosalind Advisors, Inc.S&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| DCTHDelcath Systems, Inc. | $41.6M | 15.6% | |
| FENCFennec Pharmaceuticals Inc | $34.3M | 12.9% | +9.6% |
| XERSXeris Biopharma Holdings Inc | $23.0M | 8.7% | −10.0% |
| SVRASavara Inc | $19.6M | 7.4% | |
| VSTMVerastem Inc | $15.2M | 5.7% | +86.4% |
| XFORX4 Pharmaceuticals Inc | $15.0M | 5.6% | |
| EYPTEyepoint Pharmaceuticals Inc | $14.1M | 5.3% | −4.7% |
| Cybin IncCUSIP 23256X407 | $12.9M | 4.9% | +27.7% |
| VORVor Biopharma Inc | $11.9M | 4.5% | −7.3% |
| PCVXVaxcyte Inc | $11.6M | 4.4% | −31.0% |
| Mediwound LtdCUSIP M68830112 | $11.0M | 4.1% | |
| CLDXCelldex Therapeutics Inc | $7.4M | 2.8% | −39.4% |
| BCRXBiocryst Pharmaceuticals Inc | $7.2M | 2.7% | −21.8% |
| PROFProfound Medical Corp | $5.5M | 2.1% | |
| TLPHTalphera Inc | $5.3M | 2.0% | +54.1% |
| AVIRAtea Pharmaceuticals Inc | $5.0M | 1.9% | −8.6% |
| MYOMyomo Inc | $3.8M | 1.4% | −5.4% |
| OVIDOvid Therapeutics Inc | $3.0M | 1.1% | |
| NRXSNeuraxis Inc | $3.0M | 1.1% | +77.6% |
| ABVXAbivax Sa | $2.8M | 1.0% | New |
| NSPRInspiremd Inc | $2.7M | 1.0% | |
| Regentis Biomaterials LtdCUSIP M8211G108 | $2.5M | 0.9% | +179.0% |
| Polypid LtdCUSIP M8001Q126 | $2.0M | 0.7% | −34.9% |
| BFRIBiofrontera Inc | $1.2M | 0.5% | +9.6% |
| KURAKura Oncology Inc | $1.1M | 0.4% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| XERSXeris Biopharma Holdings Inc | December 31, 2023 | +237.0% | $23.0M |
| DCTHDelcath Systems, Inc. | December 31, 2023 | +202.6% | $41.6M |
| SVRASavara Inc | December 31, 2024 | +100.7% | $19.6M |
| FENCFennec Pharmaceuticals Inc | December 31, 2024 | +70.1% | $34.3M |
| KURAKura Oncology Inc | March 31, 2025 | +66.2% | $1.1M |
| NRXSNeuraxis Inc | December 31, 2025 | +61.0% | $3.0M |
| OKUROnkure Therapeutics Inc | December 31, 2025 | +57.2% | $684K |
| Mediwound LtdCUSIP M68830112 | December 31, 2023 | +44.5% | $11.0M |
| TLPHTalphera Inc | December 31, 2023 | +40.1% | $5.3M |
| XFORX4 Pharmaceuticals Inc | September 30, 2025 | +36.5% | $15.0M |
Sold off last quarter
- CGONCg Oncology Inc was $6.8M
- VRDNViridian Therapeutics Inc was $4.9M
- DFTXDefinium Therapeutics Inc was $2.4M
- LPCNLipocine Inc was $1.8M
- AVTXAvalo Therapeutics Inc was $1.1M
- ANNXAnnexon Inc was $1.1M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +17.0% | +14.8% |
| March 31, 2026 | −12.9% | −4.6% |
| December 31, 2025 | +12.2% | +2.4% |
| September 30, 2025 | +20.6% | +7.8% |
| June 30, 2025 | +4.0% | +10.5% |
| March 31, 2025 | +9.1% | −4.6% |
| December 31, 2024 | +12.7% | +2.1% |
| September 30, 2024 | +11.5% | +5.4% |
| June 30, 2024 | −7.7% | +4.0% |
| March 31, 2024 | +13.0% | +10.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Rosalind Advisors, Inc. Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1622627&type=13F-HR&dateb=&owner=include&count=40CIK 1622627
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1622627/000162262726000022/Filed August 14, 2026 · accession 0001622627-26-000022